✦ LIBER ✦

O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer

✍ Scribed by Sandler, Alan B.; Mininberg, Eric; Henderson, Ted; Kim, Edward; Hong, Waun Ki; Mass, Robert; Novotny, William; Garcia, Ben; Herbst, Roy; Johnson, David

Book ID: 118571503
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 182 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)91770-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB